PASKALIUM
LOE Approachingpotassium aminosalicylate
NDAORALTABLET
Approved
Nov 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PASKALIUM (potassium aminosalicylate) is an oral tablet formulation of a small-molecule antituberculous agent approved in 1955. The mechanism of action and specific indications are not documented in available data, but historically potassium aminosalicylate has been used as a second-line agent in tuberculosis therapy. This product represents a legacy therapeutic from the mid-20th century antimicrobial era.
LOE Approaching
This legacy product faces imminent loss of exclusivity with minimal commercial infrastructure; career opportunities are limited to small maintenance teams managing decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PASKALIUM offers minimal career growth due to its approaching loss of exclusivity, legacy status, and zero linked job openings. This role suits professionals seeking stable, low-intensity portfolio management rather than launch or growth opportunities.
Product Manager (legacy portfolio)Regulatory Affairs Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.